Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study of Dabrafenib and Trametinib for Patients With BRAF Mutated Ameloblastoma

NCT02367859 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.

NCT NCT02367859
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02367859 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study of Dabrafenib and Trametinib for Patients With BRAF Mutated Ameloblastoma
Lead sponsor
Stanford University
Phase
Phase 2
Overall status
Completed
Start date
July 17, 2017
Completion date
June 26, 2019
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ameloblastoma, braf gene mutation